Ribociclib
Sign in to save this workspacePrimary targets: CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.25
Gini
0.729
CATDS
0.039
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ribociclib. Strongest target: CDK4_CYCLIN_D3 at 98.6% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CDK4_CYCLIN_D3 | 98.6% | 1.4% |
| 2 | CDK6_CYCLIN_D1 | 95.3% | 4.7% |
| 3 | CDK4_CYCLIN_D1 | 94.7% | 5.3% |
| 4 | CDK6_CYCLIN_D3 | 73.3% | 26.7% |
| 5 | CAMK2B | 59.0% | 41.0% |
| 6 | CDK8_CYCLIN_C | 55.6% | 44.4% |
| 7 | CAMK2D | 54.3% | 45.7% |
| 8 | LIMK1 | 51.0% | 49.0% |
| 9 | SIK2 | 48.8% | 51.2% |
| 10 | CDK9_CYCLIN_T2 | 46.5% | 53.5% |
| 11 | CDK19_CYCLIN_C | 46.5% | 53.5% |
| 12 | AURORA_C | 43.1% | 56.9% |
| 13 | CDK9_CYCLIN_T1 | 41.6% | 58.4% |
| 14 | CAMKK2 | 39.5% | 60.5% |
| 15 | DAPK2 | 31.6% | 68.4% |
| 16 | ERK7_MAPK15 | 31.2% | 68.8% |
| 17 | TNK1 | 30.8% | 69.2% |
| 18 | PDK2_PDHK2 | 28.4% | 71.6% |
| 19 | LYN | 24.5% | 75.5% |
| 20 | HASPIN | 24.3% | 75.7% |
Selectivity landscape
Where Ribociclib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ribociclib.
Annotations
Sign in to read and post annotations.
Loading…